CBAY Stock Summary and Trading Ideas (Cymabay Therapeutics | NASDAQ:CBAY)

CymaBay Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing therapies for patients with liver and other chronic diseases with high unmet medical need. Its product in pipeline includes two clinical stage product candidates: seladelpar (a PPARd agonist) and MBX-2982 (a GPR119 agonist).

Cymabay Therapeutics trades on the NASDAQ stock market under the symbol CBAY.

As of April 24, 2024, CBAY stock price was flat at $32.48 with million shares trading.

CBAY has a beta of 0.99, meaning it tends to be less sensitive to market movements. CBAY has a correlation of 0.04 to the broad based SPY ETF.

CBAY has a market cap of $3.73 billion. This is considered a Mid Cap stock.

Last quarter Cymabay Therapeutics reported $57,000 in Revenue and -$.35 earnings per share. This beat revenue expectation by $17,000 and missed earnings estimates by -$.04.

In the last 3 years, CBAY stock traded as high as $32.50 and as low as $1.67.

CBAY has outperformed the market in the last year with a price return of +214.1% while the SPY ETF gained +24.2%. CBAY has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +39.4% and 0.0%, respectively, while the SPY returned +4.6% and -2.7%, respectively.

CBAY support price is $32.48 and resistance is $32.48 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CBAY stock will trade within this expected range on the day.